Innovation Showcase
3D bioprinting in real applications — not in slides.
From tissue regeneration to 3D skin for cosmetics, from printed foods to functional pet snacks: an applied showcase where biofabrication takes shape in front of those who decide, develop and invest.
Sales closing soon — only 7 seats left, secured by order of payment.
Date
September 11, 2026
Time
1 PM to 6 PM
Venue
Bayer · São Paulo
The Innovation Showcase is not a traditional lecture event. It is a technology demonstration platform — a curated journey where applied science, advanced biomaterials and 3D models leave the bench and take shape in front of those who decide, develop and invest.
Here, biofabrication and 3D bioprinting meet industry and market. Each station is a proof of concept; each conversation, a potential route to co-development.
Technologies with scientific rigor and translational purpose, ready for real-world application.
Biomaterials, 3D models and biomimetic microenvironments demonstrated live.
Qualified encounters between academia, industry and co-development partners.
Biofabrication, 3D bioprinting, biomaterials and 3D in vitro models are redefining how research, validation and development happen in health, food, veterinary, dentistry, cosmetics, aesthetics and cellular agriculture. More biological relevance, less experimental rework and new routes to market.
3D in vitro models and biomimetic microenvironments bring assays closer to human biology, raising the relevance of results.
Less rework, shorter development cycles and faster decisions on safety, efficacy and differentiation.
From bench to application: biomaterials and scaffolds with the potential for scalability and clinical and industrial impact.
Technical differentiation that opens up product categories, partnerships and entry into previously inaccessible markets.
We bring together the leaders and specialists who turn science into product, decision and market — from the lab to corporate strategy.
The pipeline bottleneck isn't a lack of molecules — it's the rate at which they fail after years and hundreds of millions invested. Biomimetic 3D models and organoids exist to bring that decision forward: to kill what doesn't work sooner, not later.
Regulatory — no longer a "nice to have"
The FDA Modernization Act 2.0 (Dec 2022) removed the requirement for animal testing to approve new drugs, authorizing NAMs (New Approach Methodologies — organoids, organ-on-chip, 3D in vitro models). In Apr 2025, the FDA roadmap declared the goal of making animal studies "the exception, not the norm" in preclinical safety assessment within 3–5 years. Those who adopt alternative models now stay ahead of the regulatory curve.
~90%
of candidates entering clinical trials fail before approval
Reviews of clinical trial attrition
~US$ 2.6 bn
average cost to bring a new drug to market, over 10–15 years
Tufts Center for the Study of Drug Development
~50%
agreement between animal and human response in toxicity — half the time the animal model does not predict the human
Systematic review of preclinical studies
The pain today
Animal and 2D models delay the reading of efficacy and toxicity: costly failures appear late, already in the clinical phase, compromising budget, timeline and portfolio priority.
The gain
Human 3D models (organoids, spheroids, tumor microenvironments) screen candidates with greater biological relevance and anticipate safety/efficacy signals — reducing experimental rework and assets that only fail after years.
The pain today
Billions per year are lost in oncology trials that fail due to poor translation of preclinical models to the real human response.
The gain
Bioprinting and 3D culture platforms allow building microenvironments closer to human tissue, raising the decision-making power in oncology, ADME/Tox and compound screening.
What you take back
It's not a lecture: it's a contractable starting point.
Technical report of the demonstration
A record of what was demonstrated and how to apply it to your use case.
Proof-of-concept scope
A viable slice of your problem to test in a 3D model.
Co-development roadmap
Steps and responsibilities for a joint R&D front.
Direct technical contact
A dialogue with those who build the technology — not with a sales funnel.
The market no longer asks for "hypoallergenic" — it asks for a defensible claim. Reconstructed human skin models and 3D structuring let you prove the safety and efficacy of actives and formulations with data, answering both the regulatory requirement and the cruelty-free consumer at the same time.
Regulatory — the norm has already changed
In the European Union, Regulation (EC) 1223/2009 banned the testing of cosmetic products on animals since 2009 and the marketing of animal-tested products since March 2013. Reconstructed human skin models already have methods validated by the OECD (irritation, corrosion, phototoxicity). Cruelty-free is no longer marketing: it has become a market-access requirement and a proof of efficacy.
2013
the year of the EU-wide total ban on selling cosmetics tested on animals
Regulation (EC) 1223/2009
17.2%
CAGR of the 3D-printed skincare market — from ~US$ 864M (2025) toward US$ 4.2B (2035)
3D-printed skincare market projections
OECD
reconstructed human skin methods already validated to replace animal assays
OECD Test Guidelines (RhE)
The pain today
Fragile efficacy claims, dependence on tests the market and regulator no longer accept, and difficult differentiation on a shelf crowded with "natural" and "cruelty-free" products with no proof.
The gain
Efficacy and safety demonstrated on reconstructed human skin = a defensible claim, a stronger regulatory dossier and a cruelty-free edge the consumer sees and pays for.
The pain today
Expensive, slow development of actives and formulations, with validation that doesn't speak to the international regulatory route.
The gain
3D structuring and biomaterials accelerate penetration, irritation and performance testing — opening routes to personalization and new science-based categories.
What you take back
A concrete next step — not just a business card.
Demonstration report
What was demonstrated and how to apply it to your actives portfolio.
Proof-of-concept scope
Testing an active or formulation in a reconstructed skin model.
Co-development roadmap
A joint front for defensible claims and new categories.
Direct technical contact
Talk to the people doing the science to design the next step.
From 1 PM to 6 PM · entry for registered attendees. A continuous track of talkshows with specialists, interspersed with guided demonstrations throughout the event.
Opening talkshow · Janaina Dernowsek
Carlos Marques
Gildácio Chaves
Fernanda Sviech
Kamila Leichtweis
Janaina Dernowsek
Gildácio Chaves
William Oliveira
Thaís França
Maria Malagutti
Closing talkshow · Janaina Dernowsek
Food printing, tasting, bioprinting and equipment — guided demonstrations throughout the event.
Free parking at the event venue, inside Bayer.
Live demonstration and tasting of 3D food structuring.
A relaxed networking moment at the end of the event.
A production that unites cutting-edge biofabrication, interdisciplinary technical training and 3D food structuring — science, education and market in the same journey.
Biofabrication & regenerative medicine
A biofabrication deep-tech dedicated to regenerative microenvironments and advanced biomaterials based on human extracellular matrix. With a translational vision and application-driven development, Quantis connects tissue engineering, 3D in vitro models and regenerative medicine to concrete research and industry needs.
Education & 3D fabrication
A specialist in applied education and training in 3D fabrication, modeling and technical training. BioEdTech develops talent and interdisciplinary teams, bringing emerging technologies closer to those who need to master them in practice — from modeling to experiment.
Food design & 3D food printing
3D food printing and protein structuring with a focus on food design and new food experiences. MORPHÊ Foods translates materials science and product architecture into hands-on demonstration and technological tasting — from the extrudable ingredient to the final experience.
Sales closing soon · only 7 seats
September 11, 2026 · Bayer São Paulo. Quick registration and secure payment — your seat is confirmed by order of payment.
Original Quantis piece · built in a hands-on course
The biofabricated ear that opens this page is an original Quantis piece, built live in a hands-on course — real biomaterial, scaffold and structure. It's the difference between talking about biofabrication and putting it on the table.
Real pieces in live demonstration
You see, touch and understand — applied biofabrication, inside Bayer, in a limited space.
Scientific and regulatory grounding
3D models, organoids and reconstructed skin anchored in literature and in milestones like the FDA Modernization Act 2.0 and the OECD.
Presented by Quantis · BioEdTech · MORPHÊ
Three fronts — biofabrication, education and 3D food — already working with academia, industry and technical training.
Only 7 seats. These are hands-on demonstrations held in a limited-capacity space inside Bayer. Complete your registration and then the payment — your seat is only guaranteed after payment confirmation.
Step 1
Register your participation in the form beside
Step 2
Complete the payment to secure your seat
Investment
R$ 213.00
Secure payment via Asaas · Pix, bank slip or card
Applied science, real demonstrations, strategic networking and partnership opportunities — biofabrication and 3D technologies connecting science, industry and market.
Sales closing soon · only 7 seats left, secured by order of payment.